临沂再现1元测序仪中标，三问“野火烧不尽”的仪器政采市场

Core Viewpoint - The article highlights the persistent issue of abnormally low bidding in government procurement, particularly in the scientific instrument sector, despite the introduction of policies aimed at addressing this problem [2][14][15]. Group 1: Policy and Market Context - In early 2026, the Ministry of Finance released policies targeting abnormal low-price bidding in government procurement, aiming to promote a healthy market order [15][17]. - The policies include provisions for reviewing abnormal low bids and holding evaluators legally accountable if they fail to conduct proper reviews [17][21]. Group 2: Case Studies of Abnormal Bidding - A procurement project for a gene sequencer at Linyi Maternal and Child Health Hospital saw a bid of 1 yuan for a device with a price limit of 50,000 yuan, with the majority of costs attributed to consumables [6][11]. - Another case involved a fully automatic blood cell analyzer at Fuzhou First General Hospital, which was awarded at 1,000 yuan against a limit of 183,000 yuan, raising concerns about the legitimacy of the bidding process [11][12]. Group 3: Questions Raised - The article raises critical questions regarding the implementation of policies, the adequacy of regulatory oversight, and whether the review processes for abnormal bids are scientifically sound and transparent [14][18][20]. - It questions the clarity of penalties for bidders who engage in low-price bidding and whether existing regulations are sufficient to deter such practices [21][22]. Group 4: Implications for the Industry - The ongoing low-price bidding practices could undermine the market, driving out quality suppliers and harming the development of domestic scientific instrument manufacturers, particularly small and specialized firms [25][26].